FY2025 · ended Dec 31, 2025 · Revenue $5.82M, +66.3% YoY · Filed Mar 17, 2026
Abeona Therapeutics Inc. (ABEO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $5.8 million and net income of $71.2 million. Free cash flow was -$84.3 million. As of Jun 30, 2026 it held $146.8 million in cash and investments and $19.9 million in total debt.
Revenue (TTM)
$25.52M
+6280.0% vs year-ago TTM
Net income (TTM)
$-62.89M
-209.9% vs year-ago TTM
Operating cash flow (TTM)
$-76.44M
-15.9% vs year-ago TTM
Free cash flow (TTM)
$-81.53M
-14.4% vs year-ago TTM
EPS (TTM)
$-1.01
-200.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
57.05M
+17.5% vs prior year
Net cash
$126.95M
as of Jun 30, 2026
Operating margin
-327.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABEO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cleveland, OH
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 318306
- Former names
- PLASMATECH BIOPHARMACEUTICALS INC (until Jun 4, 2015); ACCESS PHARMACEUTICALS INC (until Aug 14, 2014); CHEMEX PHARMACEUTICALS INC (until Feb 5, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.8M | — | $3.5M | $1.4M | $3.0M |
| Operating income | -$89.4M | -$64.2M | -$47.1M | -$50.9M | -$89.8M |
| Net income | $71.2M | -$63.7M | -$54.2M | -$39.7M | -$84.9M |
| Diluted EPS | $1.01 | -$1.55 | -$2.53 | — | — |
| Operating cash flow | -$76.3M | -$56.0M | -$37.0M | -$43.5M | -$65.7M |
| Free cash flow | -$84.3M | -$58.5M | -$37.3M | -$43.6M | -$69.8M |
| Total assets | $219.6M | $108.9M | $64.0M | $64.2M | $79.6M |
| Total liabilities | $60.4M | $64.9M | $49.2M | $37.5M | $37.2M |
| Stockholders' equity | $159.2M | $44.0M | $14.8M | $26.8M | $42.4M |
| Cash and investments | $191.4M | $97.7M | $52.2M | $52.1M | $45.0M |
| Total debt | $25.0M | $23.0M | $5.4M | $7.6M | $9.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 12, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 10, 2026 | Jun 10, 2026 |
All 1000 Abeona Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.